Wednesday, February 10, 2010, 9:04am EST - Canadian Markets open in 26 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Opexa Therapeutics, Inc. (OPXA)

 On Feb 9: 1.95 USD   0.00 (0.00%)  
MORE ON OPXA
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Opexa Therapeutics, Inc. (NCM:OPXA) Delayed quote dataEdit
Last Trade: 1.95 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 1.95
Open: N/A
Bid: 1.85 x 2500
Ask: 2.09 x 100
1y Target Est: 8.00
Day's Range: N/A - N/A
52wk Range: 0.25 - 6.93
Volume: 0
Avg Vol (3m): 407,043
Market Cap: 25.17M
P/E (ttm): N/A
EPS (ttm): -1.91
Div & Yield: N/A (N/A%)
Opexa Therapeutics, Inc. (OPXA)
1d  5d  3m  6m  1y  2y  5y  max 
 Add OPXA to Portfolio   Download Data

HEADLINES
• Traders Send Select Stem Cell Shares Soaring
Indie Research (Mon, Feb 8)
• Opexa to Present at the 12th Annual BIO CEO & Investor Conference on February 8, 2010
Business Wire (Wed, Feb 3)
• Slew of Stem Cell News Helps Sector Higher
Indie Research (Mon, Jan 25)
• Fat Gains for Select Stem Cell Stocks
Indie Research (Fri, Jan 8)
• Opexa Therapeutics, Inc. Announces Closing of $5.1 Million Registered Direct Offering
Business Wire (Thu, Dec 17)
• OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Thu, Dec 17)
• Opexa Therapeutics to sell $5.1 million in shares to investors
at bizjournals.com (Thu, Dec 10)
• Opexa Therapeutics, Inc. Announces $5.1 Million Securities Offering
Business Wire (Thu, Dec 10)
• OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat
EDGAR Online (Thu, Dec 10)
• Interim Data Lifts Geron, Stem Cell Rivals Mixed
Indie Research (Tue, Dec 8)
More Headlines for OPXA...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Opexa Therapeutics, Inc., a development stage biopharmaceutical company, develops autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular diseases.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices